Back to News
Apr 6, 2026 4:00 PM

Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's Why

Denali Therapeutics (NASDAQ:DNLI) shares are down on Monday as the company announced it has regained full rights to its investigational therapy DNL593 from Takeda Pharmaceutical Co. Ltd. (NYSE:TAK)

Takeda Ends Drug Partnership For Strategic Reasons

Takeda on Friday notified Denali Therapeutics regarding the termination of their collaboration agreement to co-develop DNL593, a progranulin replacement therapy for frontotemporal dementia.

The decision is strategic and not related to efficacy or safety data, allowing Denali to regain full control over the therapy and its intellectual property.

Biomarker Results Expected By End Of 2026

“While we have greatly valued our partnership, we are pleased to regain full ownership of DNL593. We remain confident in the scientific rationale and the data generated to date, and we look forward to advancing DNL593 ...